Sign Up:

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

  Register

Overview

Already Registered? Click Here

The Future of CRISPR Cell Therapies is GMP

Tuesday, September 15th, 2020
8 am PT, 11 am ET, 17:00 CET

 

Genome editing technologies have taken hold of the life science industry, giving rise to novel life-saving therapies not previously thought possible. The number of investigational new drug filings for cell and genome editing therapies has boomed over the last few years, facilitated in large part by the efficiency and simplicity of the CRISPR system. CRISPR’s swift transition from research tool to therapeutic agent is unprecedented in translational medicine, making it one of the most important and exciting scientific breakthroughs in recent decades. In this GEN webinar, our presenters discuss what it will take to make CRISPR reagents suitable for use in human therapies, as these technologies move from the bench to the clinic.


A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Presenters

Presenter
Mark DeWitt, PhD
Project Scientist
UCLA
View Biography
Presenter
Robert Deans, PhD
Chief Scientific Officer
Synthego
View Biography
Presenter
Thomas Foti
President, Protein Business Unit
Aldevron
View Biography